Heterologous antisera and antivenins are essential biologicals: perspectives on a worldwide crisis.

The research article discusses the worldwide issue of shortage and affordability of crucial serum-based treatments, such as antivenins and antisera for diseases like rabies, tetanus, and diphtheria, especially in developing countries.

Essential Role of Antisera and Antivenins

• The study highlights the crucial role of antisera and antivenins, derived from human or animal (primarily horse) blood, in fighting different diseases like rabies, tetanus, and diphtheria where immediate immunity is needed. These substances provide passive immunity, which can be a lifesaver in situations or regions where active immunizations through vaccines are not available or affordable.
• The paper points out that homologous products, derived from human antibodies, are either not available or unaffordable in regions that need them the most. Instead, cheaper heterologous (equine) antisera serve as viable alternatives. Despite being safe for use after purification, these heterologous antisera are also running short in supply.

Challenges with Modern Solutions

• While monoclonal antibodies have been developed as an alternative to traditional antisera, their production costs make them less accessible and affordable for poorer countries.
• The paper also discusses the challenges faced in creating more equine antisera. Traditional sources are being depleted due to a combination of economic disincentives, poor reputation based on adverse reactions associated with the older, less-purified products, and protests from animal rights activists against using horses for blood extraction.

Issues Faced by Developing Countries

• The paper emphasizes the dilemma that many low-incoming countries face due to these challenges. In many cases, they are forced to produce less safe, crude antisera products due to a lack of resources or access to purified, pepsin-digested equine antisera.
• In the worst-case scenario, these developing countries might not have any specific treatments available at all, which poses serious public health concerns in those regions.